A study published in Lupus Science & Medicine examined bone mineral density (BMD) and bone turnover markers in 166 patients with systemic lupus erythematosus (SLE) who received treatment between January 2016 and December 2023. After more than 12 months of follow-up, researchers identified baseline BMD, disease activity (SLEDAI-2K), and hydroxychloroquine use as factors affecting the drug’s therapeutic response.